Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Vivo Sensitivity Screen with FDG-PET in Lymphoma and Breast Cancer
NCT03432741Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Mar 2018
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and breast cancer, sponsored by Mayo Clinic. Primary endpoint: Incidence of drug sensitivity as measured by injection site skin reaction at 3 months. Started Mar 2018; status: terminated.
02
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)breast cancer
Beyond the preview
Go deeper on NCT03432741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432741.